YOUR SEARCH FOR Text 43 RESULTS
11 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2022 Third Quarter Financial Results … (AGAVE-201) 1 Development collaboration with Cellenkos, Inc. 2 Clinical development of …
12 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2023 Third Quarter Financial Results … Phase 1 1 Development collaboration with Cellenkos, Inc. 2 Clinical development of …
13 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2025 Second Quarter Financial Results … of adult patients with advanced squamous cell carcinoma of the anal canal (SCAC) and for …
14 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… View all news Incyte Reports 2023 Fourth Quarter and Year-End … with amplification/over expression of CCNE1, a cell cycle regulator and potential predictive …
15 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… View all news Incyte Reports 2022 Fourth Quarter and Year-end … in preparation 1 Development collaboration with Cellenkos, Inc. 2 Clinical development of …
16 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2024 First Quarter Financial Results … with the potential to treat multiple mast cell-mediated diseases Conference Call and …
17 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… View all news Incyte Reports 2024 Second Quarter Financial Results … monoclonal antibody targeting programmed cell death receptor-1 (PD-1), in squamous cell …
18 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
… View all news Incyte Japan Announces Approval of Minjuvi® … the second most common, slow-growing form of B-cell non-Hodgkin lymphoma (NHL) in Japan , …
19 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation and Autoimmunity
… Explore Our Science We have a breadth of clinical trial programs across Hematology, … Lymphomas/Leukemias INCA036873 3 CD70×CD3 B-cell and T-cell lymphomas status for mobile …
20 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… View all news Incyte Reports 2024 Fourth Quarter and Year-End … lymphoma (FL), and retifanlimab in squamous cell anal carcinoma (SCAC). At least three Phase …